sB7-H4蛋白和CA125联检在卵巢癌患者中的应用价值

Applicative Value of Combined Determination on Serum sB7-H4 Protein and CA125 Levels in Patients with Ovarian Cancer

目的:探讨联检血清可溶性B7-H4蛋白(sB7-H4)和CA125水平在卵巢癌诊断中的应用价值。方法:采用ELISA测定51例卵巢癌患者、89例卵巢良性疾病患者和105例健康对照者血清sB7-H4水平,同时测定血清CA125水平,并对结果进行比较分析。结果:卵巢癌组血清sB7-H4、CA125水平均显著高于卵巢良性疾病组和健康对照组,差异有统计学意义(P<0.01);sB7-H4在早期卵巢癌(Ⅰ期～Ⅱ期)阳性率高于CA125,两者联检可提高诊断卵巢癌的敏感性。结论:sB7-H4是一种较好的预测早期卵巢癌的肿瘤标志物,其联检CA125有助于卵巢癌的早期诊断。

Objective To explore the applicative value on serum soluble BT-H4 protein and CA125 levels in patients with ovarian cancer. Methods sB7-H4 was determined by ELISA in ovarian cancer patients （ n = 51 ）, benign ovarian disease patients （ n = 89） and healthy controls（ n = 105 ）, serum CA125 was detected simultaneously also made a comparative analysis of the results. Results The levels of sBT-H4 and CA125 were significantly higher in ovarian cancer group than that in benign ovarian disease group and healthy control group,the difference indicated remarkable（P 〈0. 01 ） ,there were no significant difference between the benign ovarian disease group and healthy control group. The positive rate of sB7-H4 level manifested higher than CA125 in the early ovarian maliancies. The simultaneous determination showed the higher diagnostic sensitivity. Conclusion sBT-H4 can be a usefull tumor biomarker in prognos- tic of early ovarian cancer, it combined with CA125 might be helpful in the definite early diagnosis of ovarian cancer.